283 related articles for article (PubMed ID: 32122271)
21. Toxic epidermal necrolysis occurring with immune checkpoint inhibitors.
Gopee NH; Gourley AM; Oliphant TJ; Hampton PJ
Dermatol Online J; 2020 Aug; 26(8):. PubMed ID: 32941713
[TBL] [Abstract][Full Text] [Related]
22. PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients.
Kotwal A; Kottschade L; Ryder M
Thyroid; 2020 Feb; 30(2):177-184. PubMed ID: 31813343
[No Abstract] [Full Text] [Related]
23. [A Case of Thyroid Dysfunction and Isolated Adrenocorticotropin Deficiency after Nivolumab Therapy for Malignant Melanoma].
Nishio K; Okada Y; Kurozumi A; Tanaka Y
J UOEH; 2021; 43(1):97-102. PubMed ID: 33678791
[TBL] [Abstract][Full Text] [Related]
24. Nivolumab-induced hypothyoidism with consequent hypothyroid related myopathy.
Johnson ED; Kerrigan K; Butler K; Patel SB
J Oncol Pharm Pract; 2020 Jan; 26(1):224-227. PubMed ID: 30880569
[TBL] [Abstract][Full Text] [Related]
25. [Nivolumab-induced hypothyroidism: A case report].
Lin C; Guo Z; Mo Z
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2019 Feb; 44(2):222-224. PubMed ID: 30837393
[TBL] [Abstract][Full Text] [Related]
26. Prediction-based prompt levothyroxine replacement to prevent a hypothyroid state after immune-related adverse events involving the thyroid gland.
Yamauchi I; Hakata T; Sugawa T; Kosugi D; Fujita H; Okamoto K; Ueda Y; Fujii T; Taura D; Harada N; Inagaki N
Endocr J; 2023 Oct; 70(10):987-998. PubMed ID: 37574279
[TBL] [Abstract][Full Text] [Related]
27. Thyroid function abnormality induced by PD-1 inhibitors have a positive impact on survival in patients with non-small cell lung cancer.
Zhou Y; Xia R; Xiao H; Pu D; Long Y; Ding Z; Liu J; Ma X
Int Immunopharmacol; 2021 Feb; 91():107296. PubMed ID: 33360368
[TBL] [Abstract][Full Text] [Related]
28. Familial dysalbuminaemic hyperthyroxinaemia interferes with current free thyroid hormone immunoassay methods.
Khoo S; Lyons G; McGowan A; Gurnell M; Oddy S; Visser WE; van den Berg S; Halsall D; Taylor K; Chatterjee K; Moran C
Eur J Endocrinol; 2020 Jun; 182(6):533-538. PubMed ID: 32213658
[TBL] [Abstract][Full Text] [Related]
29. So slow, so fast, a case of nivolumab-induced hypothyroidism with subsequent rhabdomyolysis.
Abushalha K; Abulaimoun S; Silberstein PT
Immunotherapy; 2020 Jun; 12(9):625-628. PubMed ID: 32418490
[No Abstract] [Full Text] [Related]
30. Vitiligo expansion and extent correlate with durable response in anti-programmed death 1 antibody treatment for advanced melanoma: A multi-institutional retrospective study.
Matsuya T; Nakamura Y; Matsushita S; Tanaka R; Teramoto Y; Asami Y; Uehara J; Aoki M; Yamamura K; Nakamura Y; Fujisawa Y; Livingstone E; Zimmer L; Schadendorf D; Kagamu H; Fujimoto M; Honma M; Ishida-Yamamoto A; Araki R; Yamamoto A
J Dermatol; 2020 Jun; 47(6):629-635. PubMed ID: 32275100
[TBL] [Abstract][Full Text] [Related]
31. Permanent hypothyroidism following immune checkpoint inhibitors induced thyroiditis may be associated with improved survival: results of an exploratory study.
Lee HJ; Manavalan A; Stefan-Lifshitz M; Schechter C; Maity A; Tomer Y
Front Endocrinol (Lausanne); 2023; 14():1169173. PubMed ID: 37168978
[TBL] [Abstract][Full Text] [Related]
32. Higher baseline TSH levels predict early hypothyroidism during cancer immunotherapy.
Luongo C; Morra R; Gambale C; Porcelli T; Sessa F; Matano E; Damiano V; Klain M; Schlumberger M; Salvatore D
J Endocrinol Invest; 2021 Sep; 44(9):1927-1933. PubMed ID: 33576954
[TBL] [Abstract][Full Text] [Related]
33. Heterophilic antibody interference with TSH measurement on different immunoassay platforms.
Cheng X; Guo X; Chai X; Hu Y; Lian X; Zhang G
Clin Chim Acta; 2021 Jan; 512():63-65. PubMed ID: 33285118
[TBL] [Abstract][Full Text] [Related]
34. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review.
Sise ME; Seethapathy H; Reynolds KL
Oncologist; 2019 Jun; 24(6):735-742. PubMed ID: 30902916
[TBL] [Abstract][Full Text] [Related]
35. Thyroid disorders in programmed death 1 inhibitor-treated patients: Is previous therapy with tyrosine kinase inhibitors a predisposing factor?
Sbardella E; Tenuta M; Sirgiovanni G; Gianfrilli D; Pozza C; Venneri MA; Cortesi E; Marchetti P; Lenzi A; Gelibter AJ; Isidori AM
Clin Endocrinol (Oxf); 2020 Mar; 92(3):258-265. PubMed ID: 31788837
[TBL] [Abstract][Full Text] [Related]
36. Immune checkpoint inhibitors-associated risk of immune-related hypothyroidism in older patients with advanced melanoma: a real-world analysis of US SEER-Medicare data.
Almutairi AR; Erstad BL; McBride A; Slack M; Abraham I
Expert Opin Drug Saf; 2021 Apr; 20(4):489-497. PubMed ID: 33445985
[No Abstract] [Full Text] [Related]
37. Incidence of thyroid dysfunctions during treatment with nivolumab for non-small cell lung cancer: Retrospective study of 105 patients.
Campredon P; Mouly C; Lusque A; Bigay-Game L; Bousquet E; Mazières J; Caron P
Presse Med; 2019 Apr; 48(4):e199-e207. PubMed ID: 31005502
[TBL] [Abstract][Full Text] [Related]
38. Nivolumab-induced thyroid dysfunction lacking antithyroid antibody is frequently evoked in Japanese patients with malignant melanoma.
Yano S; Ashida K; Nagata H; Ohe K; Wada N; Takeichi Y; Hanada Y; Ibayashi Y; Wang L; Sakamoto S; Sakamoto R; Uchi H; Shiratsuchi M; Furue M; Nomura M; Ogawa Y
BMC Endocr Disord; 2018 Jun; 18(1):36. PubMed ID: 29884162
[TBL] [Abstract][Full Text] [Related]
39. [Amiodarone and the thyroid gland].
Bednarek-Tupikowska G; Filus A; Kuliczkowska J; Bugajski J
Postepy Hig Med Dosw (Online); 2004 Apr; 58():216-25. PubMed ID: 15114257
[TBL] [Abstract][Full Text] [Related]
40. Nivolumab-induced Thyroid Dysfunctions in Patients with Previously Treated Non-small Cell Lung Cancer.
Zhang X; Wu Y; Lv J; Li X; Ma L; Nong J; Zhang H; Qin N; Zhang Q; Shi G; Yang X; Wang J; Zhang S
Interdiscip Sci; 2019 Jun; 11(2):287-291. PubMed ID: 31187431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
